CendR

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
Financial management, FDA, University, Cancer, FOLFIRINOX, Temozolomide, CendR, Safety, Pancreatic cancer, Conference call, Research, RNA, Osteosarcoma, GBM, National Health, Tumor microenvironment, PDAC, Therapy, Patient, SOC, Neoplasm, Data analysis, Glioblastoma, Projection, Pharmaceutical industry

BASKING RIDGE, N. J., May 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.

Key Points: 
  • “2024, a pivotal year for Lisata, is off to a very strong start,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata.
  • The trial is actively enrolling with enrollment completion expected by the end of the third quarter of 2024.
  • As of March 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $43.3 million.
  • Lisata will hold a live conference call today, May 9, 2024, at 4:30 p.m. Eastern Time to discuss financial results, provide a business update and answer questions.

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Therapy, CendR, Head, Conference call, University, Neoplasm, Research, Bolster, Chemistry, CD34, National Health, FOLFIRINOX, Food, GBM, Projection, Safety, RNA, PDAC, Tumor microenvironment, Cholangiocarcinoma, Patient, Glioblastoma, Temozolomide, Pancreatic cancer, Cancer, SOC, Pharmaceutical industry

BASKING RIDGE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.

Key Points: 
  • Conference call scheduled for today at 4:30 p.m. Eastern time
    BASKING RIDGE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.
  • Lisata and its development collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
  • As of December 31, 2023, Lisata had cash, cash equivalents, and marketable securities of approximately $50.5 million.
  • Lisata will hold a live conference call on Thursday, February 29, 2024 at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Science, Parliamentary Information Technology Committee, Patient, Pleasure, CendR, Therapy, Pharmaceutical industry, Management

Dr. Ruoslahti will remain associated with the Company, however, in a scientific advisory position.

Key Points: 
  • Dr. Ruoslahti will remain associated with the Company, however, in a scientific advisory position.
  • He has served on the Company’s Board of Directors and as Chair of its Science and Technology Committee since September 2022.
  • Ruoslahti's vision and groundbreaking scientific discoveries in the integrin space have been pivotal in shaping the trajectory of Lisata Therapeutics since its inception,” stated Greg Brown, M.D., Chairman of the Board of Lisata.
  • It has been my pleasure to work with the Lisata management team and Board of Directors in advancing the clinical development of LSTA1,” stated Dr. Ruoslahti.

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Pancreatic cancer, CMD, Therapy, File, Neoplasm, Internet, Medicines and Healthcare products Regulatory Agency, COVID-19, Glomerular filtration rate, Research, Catheter, RNA, CD34, Trial of the century, Pharmaceuticals and Medical Devices Agency, Medication, Data monitoring committee, State, Patient, PMDA, Cancer, FREEDOM, Microcirculation, Kidney, Diagnosis, CendR, CLI, DKD, Tumor microenvironment, Kidney disease, Safety, Pharmaceutical industry, Cryptocurrency

We anticipate that such execution and those data will result in increased shareholder value while prompting additional attractive partnering opportunities.

Key Points: 
  • We anticipate that such execution and those data will result in increased shareholder value while prompting additional attractive partnering opportunities.
  • LSTA1 also has the potential to modify the tumor microenvironment, with the objective of making tumors more susceptible to immunotherapies.
  • We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata will hold a live conference call today, March 30, 2023, at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022
American Academy, Lasker Award, Safety, Canada Gairdner International Award, Center, City of Hope National Medical Center, Biology, Patient, Perseverance, Nasdaq, Sanford Burnham Prebys Medical Discovery Institute, Research, Disease, University of California, Santa Barbara, National Academy of Medicine, Life, DRS, CD34, Japan Prize, University of Helsinki, Tumor microenvironment, University of Turku, RGD, National Academy of Inventors, Integrin, California Institute for Quantitative Biosciences, Director, European, Neoplasm, Physiology, City, European Molecular Biology Organization, Board of directors, Tissue, GLOBE, Peptide, Health, Therapy, Thrombosis, National academy, CendR, Japan, Pancreatic cancer, Cell adhesion, Nanomedicine, Survival, Cancer, Cell, Medical research, RNA, Heart, University, Pharmaceutical industry, Technology, Science

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Retrieved on: 
Thursday, September 15, 2022
Safety, Breast, Astex, Patient, Investment, Nasdaq, Silence Therapeutics, Communication, Time, COVID-19, Sirna, Intellectual property, CD34, MBA, Annual report, SAN, Tumor microenvironment, SEC, EMA, FDA, Review, Neoplasm, Exchange, CEO, AstraZeneca, Research and development, Board of directors, Board, Security (finance), GLOBE, Caladrius Biosciences, Cancer, Therapy, Development, CendR, Colorectal cancer, Prostate, Pancreatic cancer, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Risk, Lung, RNA, Management, Pharmaceutical industry, Research, Director, Mergers and acquisitions, Caladrius, Zeneca

BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. (“Lisata”) and will focus primarily on advancing its CendR Platform™ technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs. Lisata will commence trading on The Nasdaq Capital Market today, September 15, 2022, under the ticker symbol “LSTA”.

Key Points: 
  • Lisatas cash and investments, as of immediately following the closing of the merger, are approximately $76 million.
  • Prior to the closing of the merger, Caladrius effected a 1-for-15 reverse split of its common stock.
  • Pursuant to the merger agreement and upon the closing of the merger, three former Cend directors, including Erkki Ruoslahti, M.D., Ph.D., Heidi Henson, and David Slack, MBA, were appointed as directors.
  • Additionally, Lisata is pleased to announce that Mohammad Azab, M.D., M.Sc., MBA has been appointed to the Lisata Board of Directors.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

Retrieved on: 
Wednesday, September 14, 2022
Therapy, Safety, Time, Nasdaq, CD34, CendR, Risk, Neoplasm, Nature, Company, Intellectual property, List of life sciences, Private Securities Litigation Reform Act, Review, Corporate action, Clinical trial, Exchange, Cancer, Technology, Plan, Annual report, Agreement, Tumor microenvironment, Security (finance), GLOBE, Caladrius Biosciences, SEC, Kidney disease, Communication, Immunosuppression, Pharmaceutical industry, Mergers and acquisitions, Caladrius

Subsequent to the stockholders approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius common stock at a ratio of one new share for every fifteen shares outstanding.

Key Points: 
  • Subsequent to the stockholders approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius common stock at a ratio of one new share for every fifteen shares outstanding.
  • Subject to the satisfaction of customary closing conditions, the closing of the merger with Cend is expected to occur on September 15, 2022.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.
  • The Company recently announced that it has signed a definitive merger agreement with Cend Therapeutics, Inc. ( www.cendrx.com ) to form Lisata Therapeutics.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Retrieved on: 
Wednesday, August 10, 2022
Telephone, CD34, Risk, GLOBE, Death, Neoplasm, Form, Failure, Drug resistance, SEC, Cancer, Integrin, Clinical trial, Annual report, Communication, Patient, Pancreatic cancer, Tumor microenvironment, CendR, Collection, Immunosuppression, Investor relations, Kidney disease, Technology, Private Securities Litigation Reform Act, Sale, Nasdaq, Neuropilin, SAN, Safety, Nature, Immunotherapy, THE, Person, Intellectual property, Drug Master File, Caladrius Biosciences, Prospectus, Roche, Therapy, Westchester Avenue, Time, Internet, Review, Company, PDAC, Pharmaceutical industry, Medical imaging, Security (finance), Caladrius

BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”) and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate Cend’s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq®), Roche’s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (“mPDAC”). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study.

Key Points: 
  • We are truly delighted to report progress regarding the development of CEND-1 supported by our collaboration agreement with Cend.
  • Caladrius commitment of resources, including its investment in Cend, provide support for this collaboration.
  • We are excited to work with Roche as Caladrius and Cend combine to form Lisata Therapeutics, stated David Mazzo, Ph.D., Chief Executive Officer of Caladrius.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Telephone, CD34, Risk, Board of directors, GLOBE, Form, Failure, SEC, Catheter, Investment, Clinical trial, CMD, Annual report, Communication, Patient, Microcirculation, Pharmaceuticals and Medical Devices Agency, Medicines and Healthcare products Regulatory Agency, CendR, CLI, Medication, Investor relations, Kidney disease, FREEDOM, Diagnosis, Private Securities Litigation Reform Act, Sale, Conference call, The Lancet, Nasdaq, Safety, Nature, Conference, THE, University, Person, Intellectual property, Trial master file, Caladrius Biosciences, DKD, Prospectus, Therapy, Cell, COVID-19, Program, Westchester Avenue, Kidney, Investor, PMDA, Time, Internet, FDA, Review, Data monitoring committee, Company, Board, Research, EDT, Pharmaceutical industry, Internet service provider, Bank, Security (finance), Caladrius

BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our proposed merger with Cend Therapeutics (Cend).
  • The Company treated the first patient in April 2022 and completed treatment for all six subjects during the third quarter of 2022.
  • Caladrius will hold a live conference call today, August 4, 2022, at 4:30 p.m. (EDT) to discuss financial results, provide a business update and answer questions.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Retrieved on: 
Wednesday, July 6, 2022
European Society for Medical Oncology, Cell, Oncology, Patient, CendR, Survivor, SOC, Saint John, Immunosuppression, GLOBE, Cancer, Progression-free survival, Toxic epidermal necrolysis, Pancreatic cancer, Pharmacokinetics, SAN, ESMO, Neoplasm, Particle-size distribution, Technology, The Lancet, Integrin, Medicine, Tumor microenvironment, Congress, Safety, St John of God Hospital Richmond, Hepatology, Neuropilin, Therapy, Pharmaceutical industry, Medical imaging

The publication details the results of an open-label, multi-center, Phase 1 trial conducted in 31 patients in the safety population and 29 patients in the efficacy population.

Key Points: 
  • The publication details the results of an open-label, multi-center, Phase 1 trial conducted in 31 patients in the safety population and 29 patients in the efficacy population.
  • The protective meshwork, or tumor stroma, that surrounds the cancer cells has proved a difficult barrier for chemotherapy drugs to penetrate.
  • The data in the publication expand on the preliminary findings presented at the 2020 European Society for Medical Oncology (ESMO) Congress.
  • Cend recently announced that it has signed a definitive merger agreement with Caladrius Biosciences, Inc. ( www.caladrius.com ) to form Lisata Therapeutics.